Dr. Shahryar Kavoussi Elagolix Treatment for Uterine Adenomyoma

Dr. Shahryar Kavoussi publishes report on elagolix use to treat a uterine adenomyoma

Elagolix (Orilissa®) is the first orally-available medication in a class of medications known as gonadotropin releasing hormone (GnRH) antagonists.  This medication has been approved by the United States Food and Drug Administration for the treatment of moderate to severe pelvic pain due to endometriosis.  In this case report, elagolix was used to treat a patient with persistent pelvic pain due to endometriosis, who also had a 3.9 centimeter uterine adenomyoma, which is a focal mass of endometrial tissue (similar to cells that line the uterine cavity) located in the myometrium (the muscle of the uterus).  After 4 months, the adenomyoma had dissolved.  Although large studies are needed in order to further evaluate the potential of this medication for this clinical scenario, this case report illustrates the potential for the therapeutic effect of elagolix on a uterine adenomyoma.

To read more about this article published in the European Journal of Obstetrics & Gynecology and Reproductive Biology, click here.